TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
cbdMD ( (YCBD) ) has issued an update.
On November 28, 2025, cbdMD, Inc. entered into an Executive Employment Agreement with its CEO and CFO, T. Ronan Kennedy, which includes a base salary and a restricted stock award contingent on shareholder approval. Additionally, the company’s board approved a new 2025 Equity Compensation Plan to replace the expired 2015 plan, aiming to incentivize key contributors with stock-based awards, subject to shareholder approval at the 2026 annual meeting.
The most recent analyst rating on (YCBD) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on cbdMD stock, see the YCBD Stock Forecast page.
Spark’s Take on YCBD Stock
According to Spark, TipRanks’ AI Analyst, YCBD is a Underperform.
The overall stock score is heavily impacted by significant financial challenges, including negative earnings and cash flow issues. Technical analysis indicates weak momentum, and valuation metrics are unfavorable due to the negative P/E ratio. These factors collectively suggest a high-risk investment.
To see Spark’s full report on YCBD stock, click here.
More about cbdMD
cbdMD, Inc. is a North Carolina-based company operating in the wellness industry, primarily focusing on the production and sale of CBD products. The company offers a range of products including tinctures, gummies, topicals, and bath bombs, targeting health-conscious consumers seeking natural alternatives for wellness and recovery.
Average Trading Volume: 3,927,956
Technical Sentiment Signal: Sell
Current Market Cap: $4.78M
See more insights into YCBD stock on TipRanks’ Stock Analysis page.